| Literature DB >> 26815786 |
Liselotte van Bloemendaal1, Richard G Ijzerman2, Jennifer S Ten Kulve2, Frederik Barkhof3, Michaela Diamant2, Dick J Veltman4, Eelco van Duinkerken2,5,6.
Abstract
Type 2 diabetes mellitus (T2DM) is characterized by obesity, hyperglycemia and insulin resistance. Both T2DM and obesity are associated with cerebral complications, including an increased risk of cognitive impairment and dementia, however the underlying mechanisms are largely unknown. In the current study, we aimed to determine the relative contributions of obesity and the presence of T2DM to altered white matter structure. We used diffusion tensor imaging (DTI) and voxel-based morphometry (VBM) to measure white matter integrity and volume in obese T2DM patients without micro- or macrovascular complications, age- gender- and BMI-matched normoglycemic obese subjects and age- and gender-matched normoglycemic lean subjects. We found that obese T2DM patients compared with lean subjects had lower axial diffusivity (in the right corticospinal tract, right inferior fronto-occipital tract, right superior longitudinal fasciculus and right forceps major) and reduced white matter volume (in the right inferior parietal lobe and the left external capsule region). In normoglycemic obese compared with lean subjects axial diffusivity as well as white matter volume tended to be reduced, whereas there were no significant differences between normoglycemic obese subjects and T2DM patients. Decreased white matter integrity and volume were univariately related to higher age, being male, higher BMI, HbA1C and fasting glucose and insulin levels. However, multivariate analyses demonstrated that only BMI was independently related to white matter integrity, and age, gender and BMI to white matter volume loss. Our data indicate that obese T2DM patients have reduced white matter integrity and volume, but that this is largely explained by BMI, rather than T2DM per se.Entities:
Keywords: Brain; DTI; Integrity; Obesity; Type 2 diabetes; VBM; Volume; White matter
Mesh:
Year: 2016 PMID: 26815786 PMCID: PMC4863900 DOI: 10.1007/s11011-016-9792-3
Source DB: PubMed Journal: Metab Brain Dis ISSN: 0885-7490 Impact factor: 3.584
Subject characteristics
| Lean ( | Obese ( | T2DM ( | ANOVA | |
|---|---|---|---|---|
| Age (years) | 57.3 ± 1.9 | 57.7 ± 2.2 | 61.4 ± 1.5 | 0.2 |
| Gender, male/female (n) | 8/7 | 8/7 | 8/8 | – |
| Weight (kg) | 71.5 ± 2.9 | 100.7 ± 3.0* | 97.9 ± 3.0* | <0.001 |
| Body mass index (kg/m2) | 23.4 ± 0.4 | 32.6 ± 0.8* | 34.0 ± 0.9* | <0.001 |
| Waist circumference (cm) | 85.7 ± 2.1 | 112.3 ± 2.2* | 115.7 ± 1.8* | <0.001 |
| Systolic blood pressure (mmHg) | 119 ± 4 | 127 ± 3 | 141 ± 3† | <0.001 |
| Diastolic blood pressure (mmHg) | 76 ± 2 | 79 ± 2 | 83 ± 2 | 0.057 |
| Fasting plasma glucose (mmol/l) | 5.2 ± 0.1 | 5.3 ± 0.1 | 8.4 ± 0.5† | <0.001 |
| Glucose 2 h after OGTT (mmol/l) | 5.1 ± 0.3 | 5.4 ± 0.2 | – | 0.4 |
| HbA1c (%) | 5.5 ± 0.03 | 5.5 ± 0.06 | 6.9 ± 0.22† | <0.001 |
| HbA1c (mmol/mol) | 37 ± 0.3 | 37 ± 0.7 | 52 ± 2.4† | <0.001 |
| Total cholesterol (mmol/l) | 5.6 ± 0.2 | 5.6 ± 0.2 | 4.5 ± 0.3† | 0.002 |
| LDL-cholesterol (mmol/l) | 3.3 ± 0.2 | 3.4 ± 0.2 | 2.3 ± 0.2† | <0.001 |
| HDL-cholesterol (mmol/l) | 1.9 ± 0.1 | 1.4 ± 0.1* | 1.3 ± 0.1* | <0.001 |
| Triglycerids (mmol/l) | 0.9 ± 0.1 | 1.7 ± 0.3 | 1.8 ± 0.3 | 0.046 |
| Fasting NEFA (mmol/l) | 0.46 ± 0.04 | 0.45 ± 0.03 | 0.64 ± 0.04† | 0.001 |
| Fasting insulin (pmol/l) | 36 ± 2.8 | 81 ± 14 | 117 ± 17† | <0.001 |
| Diabetes duration (years) | – | – | 7.0 [4.25, 10.75] | – |
| Fazekas score (0; 1; 2; 3) | 6; 7; 2; 0 | 8; 5; 2; 0 | 5; 9; 2; 0 | 0.8 |
Data are means ± SEM or median [interquartile range]
Fazekas score for white matter lesions: 0 indicates no lesions; 1 indicates punctate foci; 2 indicates beginning confluence of foci; 3 indicates large confluent areas
OGTT oral glucose tolerance test, NEFA non-esterified fatty acids, T2DM type 2 diabetes patients
*Statistically significant different from lean (post-hoc Bonferroni corrected P < 0.05)
†Statistically significant different from lean and obese (post-hoc Bonferroni corrected P < 0.05)
Fig. 1Changes in axial diffusivity in T2DM patients and obese compared with lean subjects. a Brain slices showing decreased axial diffusivity (λ1) in T2DM patients compared with lean subjects in right corticospinal tract, right inferior fronto-occipital tract, right superior longitudinal fasciculus and right forceps major; b Brain slices showing a cluster of voxels on the left side of the forceps major where axial diffusivity tended to be lower in subjects with obesity compared with controls (PFWE = 0.11). The mean skeleton is shown in green, and significant differences are displayed as thickened tracts in blue for visualization purposes. Left side of the axial slices is the right side of the brain. X, y, z are the Montreal Neurological Institute (MNI) coordinates of the brain in standard space
Fig. 2Reduced white matter volume in T2DM patients compared with lean subjects. a Brain slices showing clusters of reduced white matter volume in the external capsule region in obese T2DM patients compared with lean subjects, as determined with VBM; b Brain slices showing a cluster of reduced white matter volume in the external capsule region in obese compared with lean subjects. This cluster, however, was not statistically significant after FWE-correction for multiple comparisons (PFWE = 0.380). The color scale reflects the T-value. Right side of the axial slices is the right side of the brain. X, y, z are the Montreal Neurological Institute (MNI) coordinates of the brain in standard space
Between-group differences in white matter volume and integrity
| Region | Side | Cluster (voxels) | Volume (mL) | T | P-uncorr | P-FWE | MNI coordinates (x, y, z) | |
|---|---|---|---|---|---|---|---|---|
| White matter volume | ||||||||
| T2DM < Lean | External capsule | L | 5735 | 19.36 | 5.64 | <0.001 | <0.001 | −32,9,2 |
| 4.99 | <0.001 | <0.001 | −27,8,−13 | |||||
| 4.03 | <0.001 | <0.001 | 17,−16,33 | |||||
| Inferior Parietal Lobe | R | 3276 | 11.06 | 4.69 | <0.001 | <0.001 | 45,−42,54 | |
| 4.49 | <0.001 | <0.001 | 47,−31,30 | |||||
| 4.48 | <0.001 | <0.001 | 39,−12,36 | |||||
| Obese < Lean | External capsule | L | 903 | 3.05 | 4.62 | <0.001 | 0.380 | −32,5,−1 |
| Axial diffusivity | ||||||||
| T2DM < Lean | Corticospinal tract, inferior fronto-occipital tract, superior longitudinal fasciculus and forceps major | R | 1803 | 1.80 | 5.49 | NA | <0.05 | 22,−28,46 |
T t-statistic, P- p-value Family-Wise Error corrected for multiple comparisons, R right, L left, MNI Montreal Neurological Institute coordinates in mm
NA not applicable
Associations between white matter parameters and demographic and clinical characteristics
| Axial diffusivitya | White matter volume cluster Lb | White matter volume cluster Rb | ||||
|---|---|---|---|---|---|---|
| Spearman’s rho |
| Spearman’s rho |
| Spearman’s rho |
| |
| Age | −0.09 | 0.573 | −0.34 | 0.021 | −0.30 | 0.041 |
| Gender | 0.27 | 0.069 | 0.52 | <0.001 | 0.54 | <0.001 |
| BMI | −0.47 | 0.001 | −0.55 | <0.001 | −0.43 | 0.003 |
| Fasting glucose | −0.45 | 0.002 | −0.31 | 0.035 | −0.24 | 0.10 |
| Fasting insulin | −0.44 | 0.002 | −0.40 | 0.006 | −0.30 | 0.040 |
| HbA1c | −0.38 | 0.008 | −0.42 | 0.004 | −0.38 | 0.010 |
| HDL | 0.27 | 0.07 | 0.17 | 0.3 | 0.15 | 0.35 |
aMean axial diffusivity value for the significant voxels in the comparison between T2DM patients and lean controls
bMean white matter volume of the two significant VBM clusters in the comparison between T2DM patients and lean controls. With these values correlations with biomedical variables were calculated in all subjects (lean, obese and T2DM)